Overview
AVIR market data
Price History
AVIR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.00 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.39 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 34.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.78 – $6.45 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $401.7M · P/B 1.01 · P/S 1.14.
Company News
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7Benzinga · Aug 13, 2026, 2:15 PM
Atea Pharmaceuticals Q2 EPS $(0.41) Beats $(0.56) EstimateBenzinga · Aug 12, 2026, 8:07 PM
Atea Pharmaceuticals shares are trading lower. The company announced topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis C virus infection.Benzinga · Jul 28, 2026, 6:36 PM
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal TrialBenzinga · Jul 28, 2026, 2:13 PM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jul 28, 2026, 11:25 AM
Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and VelpatasvirBenzinga · Jul 28, 2026, 11:09 AM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News PendingBenzinga · Jul 28, 2026, 10:55 AM
Atea Pharmaceuticals Initiates First-in-human Phase 1 Clinical Trial Of AT-587 For Hepatitis E Virus InfectionBenzinga · Jul 14, 2026, 11:05 AM
Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America, Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus InfectionBenzinga · Jun 25, 2026, 11:15 AM
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026Globenewswire Inc · May 27, 2026, 11:15 AM